Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.Pierre Brissot, D. Alberti, M. de Montalembert et al.|Blood|2005Cited by 10
Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.Yves Deugnier, J. Ford, Bruno Turlin et al.|Blood|2005Cited by 8
Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.Emanuele Angelucci, J. Ford, Bruno Turlin et al.|Blood|2005Cited by 6
189 EFFECT OF IRON CHELATION THERAPY WITH DEFERASIROX (EXJADE®, ICL670) OR DEFEROXAMINE ON HEPATOCELLULAR INFLAMMATION AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONDEPENDENT ANEMIAYves Deugnier, Pierre Brissot, Bruno Turlin et al.|Journal of Hepatology|2008Cited by 3